BridgeWell Briefs #6: LDN and Weight Loss: Don't Borrow the Evidence

The Integrative Clinician by BridgeWell · Sep 22, 2026 · 6m · transcript

Low-dose naltrexone is showing up more and more in conversations about weight loss. But are we borrowing evidence from a different treatment?

In this BridgeWell Brief, we look at the important distinction between the FDA-approved naltrexone plus bupropion combination used for weight management and low-dose naltrexone used on its own.

LDN has interesting proposed mechanisms involving opioid signaling, immune modulation, and neuroinflammation. But mechanism is not the same thing as evidence for meaningful weight loss.

The clinical pearl is simple:

Don’t borrow evidence across formulations…